The Effectiveness of Risankizumab as Induction Therapy for Crohn’s Disease: Data From the Sicilian Network for Inflammatory Bowel Diseases
Year: 2024
Type: article
Study design: Observational Study
Abstract: Lay Summary This multicentre cohort study showed that Risankizumab is an effective induction therapy in patients with Crohn’s disease, and that the best results are obtained when Risankizumab is used as second-line therapy following a previous failure with a TNF inhibitor.
Source: Inflammatory Bowel Diseases
DOI: 10.1093/ibd/izae248
Authors: Fabio Salvatore Macaluso, Sara Renna, Walter Fries, Anna Viola, Maria Cappello, Ivan Alberto Salerno, Filippo Mocciaro, Barbara Scrivo, Emiliano Giangreco, Concetta Ferracane, Maria Giovanna Minissale, Maria Emanuela Distefano, Vincenza Tortorella, Alessandro Termini, Luca Bertoncello, Ambrogio Orlando
Institutions: Ospedale Vincenzo Cervello, Azienda Ospedaliera Universitaria Policlinico "G. Martino", University of Palermo, University of Palermo, Ospedale Maria Vittoria, Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco", Ospedale Buccheri la Ferla Fatebenefratelli, Ospedale Cannizzaro, Azienda Ospedaliera Ospedali Riuniti Papardo Piemonte
Language: English
Topic: Inflammatory Bowel Disease
Subfield: Genetics
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W4403788959